REFERENCES
- Abalos E, Cuesta C, Grosso AL, Chou D, Say L. Global and regional
estimates of preeclampsia and eclampsia: a systematic review. Eur J
Obstet Gynecol Reprod Biol. 2013;170:1-7.
- Hutcheon JA, Lisonkova S, Joseph KS. Epidemiology of pre-eclampsia and
the other hypertensive disorders of pregnancy. Best Pract Res Clin
Obstet Gynaecol. 2011;25:391-403.
- Lisonkova S, Joseph KS. Incidence of preeclampsia: risk factors and
outcomes associated with early- versus late-onset disease. Am J Obstet
Gynecol. 2013;209:544.e1-12.
- Steegers EAP, von Dadelszen P, Duvekot JJ, Pijnenborg R.
Pre-eclampsia. Lancet. 2010;376:631-44.
- Chappell LC, Cluver CA, Kingdom J, Tong S. Pre-eclampsia. Lancet.
2021;398:341-54.
- Hofmeyr GJ, Lawrie TA, Atallah ÁN, Torloni MR. Calcium supplementation
during pregnancy for preventing hypertensive disorders and related
problems. Cochrane Database Syst Rev. 2018;10:CD001059.
- Ceulemans M, Van Calsteren K, Allegaert K, Foulon V. Health products’
and substance use among pregnant women visiting a tertiary hospital in
Belgium: A cross-sectional study. Pharmacoepidemiol Drug Saf.
2019;28:1231-8.
- Meyer A, Fermaut M, Drouin J, Carbonnel F, Weill A. Drug use for
gastrointestinal symptoms during pregnancy: A French nationwide study
2010-2018. PLoS One. 2021;16:e0245854.
- Onda K, Tong S, Beard S, Binder N, Muto M, Senadheera SN, et al.
Proton pump inhibitors decrease soluble fms-like tyrosine kinase-1 and
soluble endoglin secretion, decrease hypertension, and rescue
endothelial dysfunction. Hypertension. 2017;69:457-68.
- Saleh L, Samantar R, Garrelds IM, van den Meiracker AH, Visser W,
Danser AHJ. Low soluble fms-like tyrosine kinase-1, endoglin, and
endothelin-1 levels in women with confirmed or suspected preeclampsia
using proton pump inhibitors. Hypertension. 2017;70:594-600.
- Hastie R, Bergman L, Cluver CA, Wikman A, Hannan NJ, Walker SP, et al.
Proton pump inhibitors and preeclampsia risk among 157 720 women.
Hypertension. 2019;73:1097-103.
- Bello NA, Huang Y, Syeda SK, Wright JD, D’Alton ME, Friedman AM.
Receipt of proton-pump inhibitors during pregnancy and risk for
preeclampsia. Am J Perinatol. 2021;38:1519-25.
- Choi A, Noh Y, Park SH, Choe SA, Shin JY. Exploration of proton pump
inhibitors use during pregnancy and preeclampsia. JAMA Netw Open.
2021;4:e2124339.
- Van Gelder MMHJ, Bretveld RW, Roukema J, Steenhoek M, van Drongelen J,
Spaanderman MEA, et al. Rationale and design of the PRegnancy and
Infant DEvelopment (PRIDE) Study. Paediatr Perinat Epidemiol.
2013;27:34-43.
- Van Gelder MMHJ, Merkus PJFM, van Drongelen J, Swarts JW, van de Belt
TH, Roeleveld N. The PRIDE Study: Evaluation of online methods of data
collection. Paediatr Perinat Epidemiol. 2020;34:484-94.
- Vorstenbosch S, te Winkel B, van Gelder MMHJ, Kant A, Roeleveld N, van
Puijenbroek E. Aim and design of pREGnant, the Dutch Pregnancy Drug
Register. Drug Saf. 2019;42:1-12.
- Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Perucca E, et
al. Comparative risk of major congenital malformations with eight
different antiepileptic drugs: a prospective cohort study of the EURAP
registry. Lancet Neurol. 2018;17:530-8.
- Von Dadelszen P, Magee LA, Roberts JM. Subclassification of
preeclampsia. Hypertens Pregnancy. 2003;22:143-8.
- De Boer J, Zeeman K, Verhoeven C. [KNOV guideline: Hypertensive
disorders during pregnancy, delivery, and puerperium]
[Internet]. Utrecht: Koninklijke Nederlandse Organisatie van
Verloskundigen; c2012 [cited 2022 Mar 25]. Available from:
https://assets.knov.nl/p/557056/none/PDF%20Vakkennis/KNOV_Standaard_Hypertensie_versie2012.pdf.
Dutch.
- Beekers P, Jamaladin H, van Drongelen J, Roeleveld N, van Gelder MMHJ.
Data from web-based questionnaires were valid for gestational diabetes
and preeclampsia, but not gestational hypertension. J Clin Epidemiol.
2020;125:84-90.
- WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD
Index 2022 [Internet]. Oslo: Norwegian Institute of Public Health;
c2021 [cited 2022 Mar 25]. Available from:
https://www.whocc.no/atc_ddd_index/.
- Van Gelder MMHJ, Vorstenbosch S, te Winkel B, van Puijenbroek EP,
Roeleveld N. Using web-based questionnaires to assess medication use
during pregnancy: A validation study in 2 prospectively enrolled
cohorts. Am J Epidemiol. 2018;187:326-36.
- Wood ME, Lupattelli A, Palmsten K, Bandoli G, Hurault-Delarue C,
Damase-Michel C, et al. Longitudinal methods for modeling exposures in
pharmacoepidemiologic studies in pregnancy. Epidemiol Rev.
2021;43:130-46.
- Genolini C, Falissard B. KmL: a package to cluster longitudinal data.
Comput Methods Programs Biomed. 2011;104:e112-21.
- Genolini C, Alacoque X, Sentenac M, Arnaud C. kml and kml3d: R
packages to cluster longitudinal data. J Stat Softw. 2015;65:1-34.
- Palmsten K, Rolland M, Hebert MF, Clowse MEB, SChatz M, Xu R, et al.
Patterns of prednisone use during pregnancy in women with rheumatoid
arthritis: Daily and cumulative dose. Pharmacoepidemiol Drug Saf.
2018;27:430-8.
- Matok I, Azoulay L, Yin H, Suissa S. Immortal time bias in
observational studies of drug effects in pregnancy. Birth Defects Res
A Clin Mol Teratol. 2014;100:658-62.
- Platt RW, Hutcheon JA, Suissa S. Immortal time bias in epidemiology.
Curr Epidemiol Rep. 2019;6:23-7.
- Palmsten K, Bandoli G, Watkins J, Vazquez-Benitez G, Gilmer TP,
Chambers CD. Oral corticosteroids and risk of preterm birth in the
California Medicaid program. J Allergy Clin Immunol Pract.
2021;9:375-84.e5.
- Textor J, Hardt J, Knüppel S. DAGitty: a graphical tool for analyzing
causal diagrams. Epidemiology. 2011;22:745.
- Bandoli G, Palmsten K, Flores KF, Chambers CD. Constructing causal
diagrams for common perinatal outcomes: Benefits, limitations and
motivating examples with maternal antidepressant use in pregnancy.
Paediatr Perinat Epidemiol. 2016;30:521-8.
- Zou G. A modified Poisson regression approach to prospective studies
with binary data. Am J Epidemiol. 2004;159:702-6.
- Lin DY, Wei LJ. The robust inference for the Cox proportional hazards
model. J Am Stat Assoc. 1989;84:1074-8.
- Zou GY, Donner A. Extension of the modified Poisson regression model
to prospective studies with correlated binary data. Stat Methods Med
Res. 2013;22:661-70.
- Howe CJ, Cole SR, Lau B, Napravnik S, Eron JJ Jr. Selection bias due
to loss to follow up in cohort studies. Epidemiology. 2016;27:91-7.
- Syngelaki A, Bredaki FE, Vaikousi E, Maiz N, Nicolaides KH. Body mass
index at 11-13 weeks’ gestation and pregnancy complications. Fetal
Diagn Ther. 2011;30:250-65.
- Meertens LJE, Scheepers HCJ, van Kuijk SMJ, Aardenburg R, van Dooren
IMA, Langenveld J, et al. External validation and clinical usefulness
of first trimester prediction models for the risk of preeclampsia: A
prospective cohort study. Fetal Diagn Ther. 2019;45:381-93.
- Chen Q, Zhang Y, Tong M, Wu M, Snowise S, Stone P, et al.
Pre-treatment with calcium prevents endothelial cell activation
induced by multiple activators, necrotic trophoblastic debris or IL-6
or preeclamptic sera: possible relevance to the pathogenesis of
preeclampsia. Placenta. 2013;34:1196-201.
- Sukonpan K, Phupong V. Serum calcium and serum magnesium in normal and
preeclamptic pregnancy. Arch Gynecol Obstet. 2005;273:12-6.
- Jain S, Sharma P, Kulshreshtha S, Mohan G, Singh S. The role of
calcium, magnesium, and zinc in pre-eclampsia. Biol Trace Elem Res.
2010;133:162-70.
- Mackillop L. Pre-eclampsia: reducing the risk with calcium
supplements. BMJ Clin Evid. 2015;12:1402.
- Santorelli G, Whitelaw D, Farrar D, West J, Lawlor DA. Associations of
maternal vitamin D, PTH and calcium with hypertensive disorders of
pregnancy and associated adverse perinatal outcomes: Findings from the
Born in Bradford cohort study. Sci Rep. 2019;9:1205.
- Forde H, Crowley RK, McKenna MJ, Kilbane MT, Conway M, McDonnell CM,
et al. No effect of calcium and vitamin D intake on maternal blood
pressure in a healthy pregnant population. Eur J Obstet Gynecol Reprod
Biol. 2021;264:8-14.
- Xu R, Luo Y, Chambers C. Assessing the effect of vaccine on
spontaneous abortion using time-dependent covariates Cox models.
Pharmacoepidemiol Drug Saf. 2012;21:844-50.
- Daniel S, Koren G, Lunenfeld E, Levy A. Immortal time bias in drug
safety cohort studies: spontaneous abortion following nonsteroidal
antiinflammatory drug exposure. Am J Obstet Gynecol.
2015;212:307.e1-6.
- Verlohren S, Herraiz I, Lapaire O, Schlembach D, Moertl M, Zeisler H,
et al. The sFlt-1/PlGF ratio in different types of hypertensive
pregnancy disorders and its prognostic potential in preeclamptic
patients. Am J Obstet Gynecol. 2012;206:58.e1-8.
- Sibai BM, Stella CL. Diagnosis and management of atypical
preeclampsia-eclampsia. Am J Obstet Gynecol. 2009;200:481.e1-7.
- Andrade SE, Bérard A, Nordeng HME, Wood ME, van Gelder MMHJ, Toh S.
Administrative claims data versus augmented pregnancy data for the
study of pharmaceutical treatments in pregnancy. Curr Epidemiol Rep.
2017:4;106-16.
- Nohr EA, Frydenberg M, Henriksen TB, Olsen J. Does low participation
in cohort studies induce bias? Epidemiology. 2006;17:413-8.
- Nilsen RM, Vollset SE, Gjessing HK, Skjærven R, Melve KK, Schreuder P,
et al. Self-selection and bias in a large prospective pregnancy cohort
in Norway. Paediatr Perinat Epidemiol. 2009;23:597-608.
- Hatch EE, Hahn KA, Wise LA, Mikkelsen EM, Kumar R, Fox MP, et al.
Evaluation of selection bias in an internet-based study of pregnancy
planners. Epidemiology. 2016;27:98-104.
- Biele G, Gustavson K, Czajkowski NO, Nilsen RM, Reichborn-Kjennerud T,
Magnus PM, et al. Bias from self selection and loss to follow-up in
prospective cohort studies. Eur J Epidemiol. 2019;34:927-38.
- Thélin CS, Richter JE. Review article: the management of heartburn
during pregnancy and lactation. Aliment Pharmacol Ther.
2020;51:421-34.